FDA approves durvalumab with enfortumab vedotin for muscle-invasive bladder cancer

FDA approval · FDA · 2026-11-13. Number 1 in the UrologyWatch Top 5 for November 15, 2026.

FDA approved the perioperative combination of durvalumab (an immune checkpoint inhibitor) and enfortumab vedotin-ejfv for muscle-invasive bladder cancer.

Why it matters: Adds a new FDA-approved perioperative regimen option for muscle-invasive bladder cancer.

Source: FDA

The full November 15, 2026 edition · Today's urology news

Loading today's edition…